AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Edwards Lifesciences surged 5.4% on Friday to $84.04 after a pair of Wall Street firms raised their price targets on the medical device maker. The rally came on volume of 2.3M shares as BTIG and Baird both increased their targets, signaling growing confidence in the company’s outlook.
BTIG led the bullish chorus, lifting its target from $98 to $100 while maintaining a Buy rating. Baird followed with a more modest adjustment, raising its target from $85 to $87 while holding a Neutral stance. The average new price target across both firms now sits at $94, representing an average increase of 2.2% from prior levels. The dual upgrades suggest analysts are warming to Edwards’ positioning in the medical device space, though the divergence in ratings—one Buy, one Neutral—reflects split views on just how much upside remains.
The move adds momentum to a stock with a market cap of $48.5B that has navigated a complex landscape for medical device manufacturers. With the average analyst target now at $94, the stock still has meaningful room to run from its current $84.04 level. The Baird Neutral rating at a target of $87 suggests some firms see limited near-term appreciation, while BTIG’s $100 target implies conviction in the company’s growth trajectory. The volume of 2.3M shares on Friday indicates heightened investor interest in the wake of the analyst actions.
Edwards operates in the medical devices space, where innovation cycles and clinical data can drive significant revaluations. The company’s 5.4% Friday gain underscores how analyst sentiment shifts can move stocks, particularly when multiple firms adjust targets simultaneously. The modest average increase of 2.2% in price targets suggests incremental optimism rather than a wholesale reassessment of the bull case.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.
